louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01456299: Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil
Official title: Target-controlled Infusion of Remifentanil for Laryngeal Mask Airway Insertion During Sevoflurane Induction in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laryngismus
Keywords: laryngeal mask airway
insertion
sevoflurane
remifentanil
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2011-10-20
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study was to determine the most suitable effect-site concentration of remifentanil for the LMA insertion during inhaled induction with 8% sevoflurane in adults.

Detailed description: For practical purposes, opioids with the ability to suppress upper airway reflexes have been used to facilitate insertion of the LMA during anaesthesia induction. To date, however, there have been no published reports addressing the use of remifentanil to facilitate LMA insertion during sevoflurane inhalation induction in adults. Therefore, the purpose of this study was to determine the most suitable effect-site concentration of remifentanil target-controlled infusion (TCI) for the LMA insertion during inhaled induction with 8% sevoflurane in adults.

Eligibility criteria: Inclusion Criteria:

- Adult patients, aged 18-60 with ASA physical status I or II, who were scheduled to minor elective surgery (\< 1 h) were considered for the study

Exclusion Criteria:

- Exclusion criteria were allergies to the study drugs, a history of gastric reflux, a history of drug abuse, obesity (body mass index \> 30 kg/m2) and suspected difficult airway

Primary outcomes:
measure: LMA Insertion Condition
timeFrame: at that time on LMA insertion only
Secondary outcomes:
measure: Frequency of Apnea
timeFrame: baseline, 30sec after drug injection
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: Ajou University School of Medicine
Study officials:
affiliation: Ajou University School of Medicine
name: Jong Yeop Kim, MD,PhD
role: STUDY_DIRECTOR
affiliation: Ajou Universiy School of Medicine
name: Jong Yeop Kim, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Sivalingam P, Kandasamy R, Madhavan G, Dhakshinamoorthi P. Conditions for laryngeal mask insertion. A comparison of propofol versus sevoflurane with or without alfentanil. Anaesthesia. 1999 Mar;54(3):271-6. doi: 10.1046/j.1365-2044.1999.00663.x.
Clinical trial NCT04967599: Alcohol Metabolism and Disease Risk in Asians
Official title: Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic/Genotypic Feedback and Motivational Processes on Early Drinking Trajectories
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2021-07-19
Enrollment: 360
Sex: ALL
Minimum age (years): 17
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary pathway of alcohol metabolism involves two main enzymes, alcohol and aldehyde dehydrogenase. Several genes that encode these enzymes have variants that alter the rate of alcohol metabolism and increase levels of acetaldehyde. The variant ALDH2\*2 allele is associated with the flushing response (i.e., Asian glow) and is found almost exclusively in individuals of east Asian descent. Although having variant ALDH2 alleles is protective against heavy drinking and alcohol use disorders, for those who do drink, these variants also are associated with elevations in risk for several health problems. The premise of this study is that we can affect early drinking behavior through personalized communication about these health-related risks.


Eligibility criteria: Inclusion Criteria:

* All participants will be of Asian heritage (i.e. Chinese/Taiwanese, Japanese, Korean, Vietnamese).
* About half of the sample will be incoming first-year undergraduates
* About half of the sample will be current undergraduates who self-report having flushed when they first started drinking alcohol

Primary outcomes:
measure: Peak Number of Alcohol Drinks Consumed in a Day
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
Secondary outcomes:
measure: Number of Drinking Days
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
measure: Number of Alcoholic Drinks Consumed on Weekend
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
measure: Number of Alcoholic Drinks Consumed Weekly
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
measure: Number of Participants Identified as Non-drinkers
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
measure: Alcohol Flush Cure Use Rate
timeFrame: Baseline through 10-months post-intervention (which occurred on 1 day)
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: Susan E. Luczak, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01376999: Step Up Versus Step Down in Controlled Ovarian Stimulation
Official title: Step Up Versus Step Down in Controlled Ovarian Stimulation for Intrauterine Insemination. A Controlled Randomised Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: No Explained Sterility
Keywords: Sterility
FSH-r
intrauterine insemination
unexplained sterility
Lead sponsor: Parc de Salut Mar
Sponsor class: OTHER
First posted: 2011-06-20
Enrollment: 158
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate if the Step up protocol is equal or superior regarding efficacy and security than the step down protocol. In couple submitted two intrauterine insemination.


Eligibility criteria: Inclusion Criteria:

* Women with unexplained sterility with needs of intrauterine insemination.

Exclusion Criteria:

* Contraindications to intrauterine insemination.

Primary outcomes:
measure: Ovulation rate
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital del Mar
Study officials:
References:
Clinical trial NCT05101499: Study on Akin Osteotomy: Fixation Versus Non-fixation (Fixakin)
Official title: Randomized Study on Akin Osteotomy: Fixation Versus Non-fixation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Akin Osteotomy
Hallux Valgus
Lead sponsor: Ramsay Générale de Santé
Sponsor class: OTHER
Collaborators: name: Clinique Blomet
name: European Clinical Trial Experts Network
First posted: 2021-11-01
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We hypothesize that the Akin screw fixation osteotomy technique provides better postoperative mobility of the metatarsophalangeal hallux joint compared to the non-fixation technique.

Detailed description: Compare the screw fixation technique of Akin's osteotomy, compared to the technique without fixation, on the postoperative mobility of the metatarsophalangeal joint of the hallux at one year postoperatively in patients ( patients operated on for an isolated hallux valgus, that is to say without any associated lateral movement, by percutaneous technique (MICA or PERC).

Eligibility criteria: Inclusion Criteria:

* Patient over 18 years-old
* Patient undergoing percutaneous surgery for Hallux valgus with first hybrid and / or percutaneous ray procedure without rotation disorder,
* First line surgery,
* Absence of metatarsophalangeal osteoarthritis,
* Persistence of mobility of the hallux metatarsophalangeal gland,
* Subject benefiting from a social protection insurance
* Patient having signed the free and informed consent / Patient having given his express consent / Patient having been informed and not opposing this research.

Exclusion Criteria:

* Rotation disorder,
* Rheumatoid foot,
* Hallux rigidus.
* Patient participating in another clinical study
* Minors:
* Adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision;
* Pregnant, breastfeeding or parturient woman;
* Hospitalized without consent.

Primary outcomes:
measure: Overall mobility of the metatarsophalangeal hallux joint in degre
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: BLOMET clinic
state: IDF
Study officials:
References:
Clinical trial NCT06985199: Culturally-adapted Mobile Health Intervention for Hypertension Care
Official title: AHOMKA Qualitative Study For Adaptation of the Medtronic Empower Health Platform
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Hypertension
Keywords: hypertension, mobile health
Lead sponsor: Tufts University
Sponsor class: OTHER
Collaborators: name: University of Ghana Medical School
name: Beth Israel Deaconess Medical Center
name: University of Health and Allied Sciences
First posted: 2025-05-22
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: A single-arm study to assess the ability of the AHOMKA platform for hypertension management to affect blood pressure change among urban and rural patients in Ghana.


Eligibility criteria: Inclusion Criteria:

* diagnosis of hypertension

Exclusion Criteria:

* Comorbidities

Primary outcomes:
measure: Change in Blood Pressure levels from Baseline
timeFrame: Baseline, 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Accra
country: Ghana
facility: National Cardiothoracic Center
city: Ho
country: Ghana
facility: Cardiothoracic Center - Outpatient Department
Study officials:
affiliation: Tufts University
name: Valencia Koomson
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Ghana
name: Mark Tettey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00875199: Contingency Management to Promote Weight Loss in Low Income Adults
Official title: Contingency Management to Promote Weight Loss in Low Income Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Overweight
Keywords: Overweight
Obesity
Contingency Management
Lead sponsor: UConn Health
Sponsor class: OTHER
First posted: 2009-04-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the feasibility and provide preliminary evidence for efficacy of a 12-week contingency management intervention to promote weight loss in overweight and obese low income adults in a community-based clinic. The study has three primary goals: (a) to determine if the contingency management treatment can be effectively applied to a new application, weight loss; (b) to obtain preliminary evidence for contingency management's efficacy in promoting weight loss and improving treatment retention, diet quality, physical activity levels, and self efficacy; and (c) to identify barriers and challenges to implementing contingency management for weight loss among low income patients.


Eligibility criteria: Inclusion Criteria:

* age between 18 and 55 years
* body mass index in kg/m2 (BMI) between 25 and 39.9
* resting blood pressure between 90/60 and 140/90
* ability to speak English and read at the 6th grade level
* willingness to be randomly assigned to one of two groups

Exclusion Criteria:

* any serious acute or chronic medical problems that may impact dietary or exercise regimens
* psychiatric conditions

Primary outcomes:
measure: absolute and relative weight loss
timeFrame: pre-treatment, weekly during active phase, post-treatment
measure: number of participants achieving clinically significant weight loss (5% or more of baseline weight)
timeFrame: pre-treatment, weekly during active phase, post-treatment
Secondary outcomes:
measure: retention
timeFrame: during active phase
measure: changes on measures of diet quality, physical activity, and self-efficacy
timeFrame: pre-treatment, post-treatment
measure: self-reports, focus groups
timeFrame: pre-treatment, post-treatment
Other outcomes:
Locations:
city: Farmington
country: United States
facility: University of Connecticut Health Center
state: Connecticut
Study officials:
affiliation: UConn Health
name: Danielle M Barry, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03948399: The Prevalence of a Low Ankle-Brachial Index in Acute Cerebral Ischemia.
Official title: The Prevalence of a Low Ankle-Brachial Index in Patients With Acute Cerebral Ischemic Event.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Stroke
Keywords: Ischemic Stroke
TIA
ABI
LEAD
Lead sponsor: Jan Biziel University Hospital No 2 in Bydgoszcz
Sponsor class: OTHER
First posted: 2019-05-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients attending to hospital settings diagnosed with acute ischemic event (stroke or TIA) and control group individuals undergo computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, lipid profile, had stroke risk factors assessed.

Brief summary: Aim of the study is assessment the prevalence of the low ankle-brachial index (ABI) defined less than or equal 0.9 in patients with acute cerebral ischemic event (stroke or transient ischemic attack) and determinate the correlation between ABI and internal carotid artery stenosis (ICAS) in the acute cerebral ischemic patients.

The low ABI is a strong marker of generalized atherosclerosis. LEAD is a strong independent predictor for stroke.

Detailed description: Aim of the study is assessment the prevalence of the low ankle-brachial index (ABI) defined less than or equal 0.9 in patients with acute cerebral ischemic event (stroke or transient ischemic attack) and determinate the correlation between ABI and internal carotid artery stenosis (ICAS) in the acute cerebral ischemic patients.

The ABI is a non-invasive tool useful for the diagnosis of LEAD. The low ABI is a strong marker of generalized atherosclerosis. LEAD is a strong independent predictor for stroke. Significant ICAS is prevalent among patients having LEAD. Acute ischemic stroke due to significant ICAS has poor prognosis.

Patients with LEAD may be a suitable subgroup for screening for ICAS using duplex scanning.

Estimating the relationship between cerebral ischemic event and the ABI value could help better guide preventive and risk reduction strategies.

Eligibility criteria: Inclusion Criteria:

* Acute ischemic stroke or transient ischemic attack of anterior circulation
* Consent of patient

Exclusion Criteria:

* primary intracranial hemorrhage,
* venous sinus thrombosis,
* unconsciousness,
* intubation,
* inability to provide and write a consent application form.

Primary outcomes:
measure: ABI
timeFrame: 7 days
Secondary outcomes:
measure: ABI/ICAS
timeFrame: 7 days
Other outcomes:
Locations:
city: Bydgoszcz
country: Poland
facility: Department of Neurosurgery and Neurology University Hospital nr 2 Collegium Medicum Nicolaus Copernicus University
Study officials:
affiliation: Jan Biziel University Hospital Collegium Medicum Nicolaus Copernicus University
name: Paweł Sokal, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03089099: Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
Official title: Development of a Prognostic Model for High Volume Metastatic Castration-Resistant Prostate Cancer Patients by Sequentially Analyzing the Expression of Molecular Markers in Circulating Tumor Cells
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer Metastatic
Keywords: Metastatic Castration-Resistant Prostate Cancer
circulating tumor cells
Prognosis
Liquid biopsy
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2017-03-24
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with newly Diagnosed High Volume Metastatic Castration-Resistant Prostate Cancer.

Brief summary: As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells (CTCs) can show how a patient's cancer responded to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of molecular markers in high volume circulating tumor cells in metastatic castration-resistant prostate cancer patients can predict the therapeutic effects and outcomes of these patients.


Eligibility criteria: Inclusion Criteria:

1. Male patients
2. 18 yrs and older, and 80 yrs and younger
3. Histologically or cytologically proven prostate adenocarcinoma;
4. Imaging examinations including Emission Computed Tomography (ECT), Positron Emission Tomography (PET) and so on revealed a high-volume disease of patients(A high-volume of disease was defined by the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis)
5. Have been received hormonal therapy and progressed into castration-resistant stage
6. Not yet receiving chemotherapy
7. Patients are willing to participate and can be followed up regularly

Exclusion Criteria:

1. Received the treatment of abiraterone acetate previously
2. Patients received chemotherapy previously
3. Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years).

Primary outcomes:
measure: overall survival
timeFrame: 2 years
Secondary outcomes:
measure: time to prostate specific antigen (PSA) progression
timeFrame: 2 years
measure: time to radiographic progression
timeFrame: 2 years
measure: complete serologic response rate at 3 month and 6 month
timeFrame: 1 year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: Fudan University
name: Dai Bo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01471899: Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Official title: Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Back Pain
Lead sponsor: EMS
Sponsor class: INDUSTRY
First posted: 2011-11-16
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drugs in the treatment of patients diagnosed with moderate to severe back pain treatment.

Detailed description: * double-blind, double-dummy, non-inferiority, prospective, parallel group, intent to treat trial.
* Experiment duration: 04 days.
* 03 visits (days 0, 2 and 4).
* Efficacy will be evaluated for back pain relief based on visual analogic scale.
* Adverse events evaluation.

Eligibility criteria: Inclusion Criteria:

* Consent of the patient or legal guardian.
* Men or women aged between 18 and 65.
* Diagnosis of acute low back pain with moderate to severe pain (Visual Analogic score greater than 4 cm)

Exclusion Criteria:

* fracture confirmed by X-ray
* Diagnosis of infection, fever,
* Pregnancy, lactation;
* Diagnosis of fibromyalgia;
* Hypersensitivity to ketorolac tromethamine, any of the ingredients of the formula or other Nonsteroidal anti-inflammatory

Primary outcomes:
measure: Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).
timeFrame: 4 days
Secondary outcomes:
measure: Safety will be evaluated by the adverse events occurrences
timeFrame: day 4
Other outcomes:
Locations:
Study officials:
affiliation: Instituto do Coracao
name: Pérola Plaper, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02180399: Serial Measurement of Capillary Blood Lactate in the Management of Sepsis
Official title: Role of the Serial Measurement of Capillary Blood Lactate in the Management of Sepsis Outside the Intensive Care
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Keywords: Sepsis
Capillary blood lactate
Serial measurement of capillary
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2014-07-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients over age 18 with an acute systemic inflammatory response syndrome array of presumed infectious not yet been treated.

Brief summary: Determination of capillary lactate by using "point-of-care" technique is accessible, fast and allows to quantify the circulatory and metabolic dysfunction caused by sepsis. Compared to conventional assay techniques in arterial blood, capillary assay technique may have an increased susceptibility to metabolic alterations induced by sepsis in its initial stages. This increased sensitivity is not necessarily relevant in the management of the most serious patients for whom the diagnosis is obvious, but it could be very useful in patients for whom a diagnosis of severe sepsis or shock have not yet been adopted, particularly to help better identify patients who would require intensive management and avoid the installation of these serious disorders.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Installation without any plausible explanation of at least one of the following clinical criteria:

  * Chills, fever, mottling, respiratory rate\> 20/min; Sat02 \< 90% or \> 94% with more than 4l O2, heart rate \> 90/min,systolic blood pressure \< 100 mmHg or 40 mmHg lower compared with normal values, Glasgow coma score \< 14. or: .a combination of two (or more) of clinical and laboratory criteria for sepsis.
* Signed informed consent form

Exclusion Criteria:

* Need in its current treatment of aerosol administration of beta agonists at a frequency greater than one per 8 hours;
* Targeted therapeutic measures have already stated for more than 60 minutes;
* Diagnosis other than Sepsis;
* Malignant neoplasm or other progressive disease and expected survival was less than 3 months.

Primary outcomes:
measure: measurement of capillary blood lactate
timeFrame: 72 hours after inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: SERVICE DE MED. INTERNE - DIABETE ET MALADIES METABOLIQUES, 1-place de l'Hôpital
city: Strasbourg
country: France
facility: Service de Médecine Interne - Clinique Médicale B
Study officials:
affiliation: University Hospitals of Strasbourg
name: Emmanuel ANDRES, MD, PhD
role: STUDY_DIRECTOR
References: